Total (n=112) | DPLD (n=87) | Malignant tumour (n=25) | p-value | |
Age years | 69 (27–86) | 69 (27–81) | 69 (44–86) | 0.48 |
Sex female/male n/n | 49/63 | 37/50 | 12/13 | 0.627 |
Height cm | 161 (139–179) | 161 (141–179) | 160 (139–176) | 0.933 |
Weight kg | 58 (37.4–96.1) | 60.1 (37.4–96.1) | 54.2 (39.6–75) | 0.093 |
Smoking index pack-years | 31 (0.3–160) | 30 (0.3–120) | 40 (5–65) | 0.033 |
Antithrombotic drug | 12 (10.7) | 10 (11.1) | 2 (9.1) | 0.607 |
Thrombocytes 1000·μL−1 | 25.3 (10–85.8) | 25.1 (10–85.8) | 25.8 (14.3–43.6) | 0.629 |
Prothrombin time (INR) | 0.97 (0.79–1.5) | 0.97 (0.79–1.5) | 0.92 (0.82–1.06) | 0.006 |
Activated partial thromboplastin time s | 30.9 (21.4–66.6) | 31.9 (21.4–66.6) | 28.1 (22.6–58.5) | 0.079 |
KL-6 U·mL−1 | 560 (104–9516) | 584 (104–9516) | - | - |
SP-D ng·mL−1 | 175.5 (17.2–1050) | 173 (7.6–1050) | - | - |
CEA ng·mL−1 | 4.4 (1–507) | - | 4.4 (1–507) | - |
CYFRA ng·mL−1 | 1.8 (0.6–71.9) | - | 1.8 (0.6–71.9) | - |
ProGRP pg·mL−1 | 44.5 (23.1–206) | - | 44.5 (23.1–206) | - |
FVC L | 2.78 (1.16–4.68) | 2.54 (1.16–4.68) | 3.13 (1.96–3.64) | 0.024 |
FVC % pred | 93.5 (38.4–151.9) | 90.2 (38.4–151.9) | 102.4 (84–149.4) | 0.001 |
FEV1 L | 2.07 (0.89–4.06) | 1.93 (0.89–4.06) | 2.23 (1.07–3.26) | 0.188 |
FEV1 % pred | 90.3 (37.1–219.1) | 88.5 (37.1–196) | 95.4 (60.85–219.1) | 0.141 |
FEV1/FVC % | 80.3 (37–119.5) | 81.4 (37–119.5) | 77.5 (49.3–118) | 0.136 |
DLCO % pred | 79.9 (14.9–197.4) | 73.1 (16.4–155.8) | 99.85 (14.86–197.4) | 0.033 |
Data are presented as n (%) or median (range), unless otherwise stated. DPLD: diffuse parenchymal lung disease; INR: international normalised ratio; KL-6: Krebs von den Lungen-6; SP-D: surfactant protein-D; CEA: carcinoembryonic antigen; CYFRA: cytokeratin 19 fragment; ProGRP: progastrin releasing peptide; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; DLCO: diffusing capacity for carbon monoxide; % pred: % predicted.